{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T02:54:17Z","timestamp":1793933657090,"version":"4.8.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,8,19]],"date-time":"2020-08-19T00:00:00Z","timestamp":1597795200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,8,19]],"date-time":"2020-08-19T00:00:00Z","timestamp":1597795200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004588","name":"Istituto Pasteur-Fondazione Cenci Bolognetti","doi-asserted-by":"crossref","award":["Ferretti"],"award-info":[{"award-number":["Ferretti"]}],"id":[{"id":"10.13039\/501100004588","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Colorectal cancer (CRC) is a leading cause of cancer death. Chemoresistance is a pivotal feature of cancer cells leading to treatment failure and ATP-binding cassette (ABC) transporters are responsible for the efflux of several molecules, including anticancer drugs. The Hedgehog-GLI (HH-GLI) pathway is a major signalling in CRC, however its role in chemoresistance has not been fully elucidated. Here we show that the HH-GLI pathway favours resistance to 5-fluorouracil and Oxaliplatin in CRC cells. We identified potential GLI1 binding sites in the promoter region of six ABC transporters, namely ABCA2, ABCB1, ABCB4, ABCB7, ABCC2 and ABCG1. Next, we investigated the binding of GLI1 using chromatin immunoprecipitation experiments and we demonstrate that GLI1 transcriptionally regulates the identified ABC transporters. We show that chemoresistant cells express high levels of GLI1 and of the ABC transporters and that GLI1 inhibition disrupts the transporters up-regulation. Moreover, we report that human CRC tumours express high levels of the ABCG1 transporter and that its expression correlates with worse patients\u2019 prognosis. This study identifies a new mechanism where HH-GLI signalling regulates CRC chemoresistance features. Our results indicate that the inhibition of Gli1 regulates the ABC transporters expression and therefore should be considered as a therapeutic option in chemoresistant patients.<\/jats:p>","DOI":"10.1038\/s41598-020-70871-9","type":"journal-article","created":{"date-parts":[[2020,8,19]],"date-time":"2020-08-19T10:03:35Z","timestamp":1597831415000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":54,"title":["Hedgehog-GLI signalling promotes chemoresistance through the regulation of ABC transporters in colorectal cancer cells"],"prefix":"10.1038","volume":"10","author":[{"given":"Agnese","family":"Po","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Citarella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppina","family":"Catanzaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zein Mersini","family":"Besharat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Trocchianesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Gianno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Sabato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Moretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"De Smaele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Vacca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micol Eleonora","family":"Fiori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Ferretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,19]]},"reference":[{"key":"70871_CR1","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/nrc.2016.126","volume":"17","author":"R Dienstmann","year":"2017","unstructured":"Dienstmann, R. et al. Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer. Nat. Rev. Cancer 17, 79. https:\/\/doi.org\/10.1038\/nrc.2016.126 (2017).","journal-title":"Nat. Rev. Cancer"},{"key":"70871_CR2","doi-asserted-by":"publisher","first-page":"3834","DOI":"10.3748\/wjg.v24.i34.3834","volume":"24","author":"K Van der Jeught","year":"2018","unstructured":"Van der Jeught, K., Xu, H.-C., Li, Y.-J., Lu, X.-B. & Ji, G. Drug resistance and new therapies in colorectal cancer. World J. Gastroenterol. 24, 3834. https:\/\/doi.org\/10.3748\/wjg.v24.i34.3834 (2018).","journal-title":"World J. Gastroenterol."},{"key":"70871_CR3","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/s41568-018-0005-8","volume":"18","author":"RW Robey","year":"2018","unstructured":"Robey, R. W. et al. Revisiting the role of ABC transporters in multidrug-resistant cancer. Nat. Rev. Cancer 18, 452\u2013464. https:\/\/doi.org\/10.1038\/s41568-018-0005-8 (2018).","journal-title":"Nat. Rev. Cancer"},{"key":"70871_CR4","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.critrevonc.2015.05.012","volume":"96","author":"M Ween","year":"2015","unstructured":"Ween, M., Armstrong, M., Oehler, M. & Ricciardelli, C. The role of ABC transporters in ovarian cancer progression and chemoresistance. Crit. Rev. Oncol.\/Hematol. 96, 220\u2013256. https:\/\/doi.org\/10.1016\/j.critrevonc.2015.05.012 (2015).","journal-title":"Crit. Rev. Oncol.\/Hematol."},{"key":"70871_CR5","doi-asserted-by":"publisher","first-page":"556","DOI":"10.3389\/fgene.2019.00556","volume":"10","author":"S Pietrobono","year":"2019","unstructured":"Pietrobono, S., Gagliardi, S. & Stecca, B. Non-canonical hedgehog signaling pathway in cancer: Activation of GLI transcription factors beyond smoothened. Front. Genet. 10, 556. https:\/\/doi.org\/10.3389\/fgene.2019.00556 (2019).","journal-title":"Front. Genet."},{"key":"70871_CR6","doi-asserted-by":"publisher","first-page":"8","DOI":"10.17305\/bjbms.2018.2756","volume":"18","author":"AM Skoda","year":"2018","unstructured":"Skoda, A. M. et al. The role of the Hedgehog signaling pathway in cancer: A comprehensive review. Bosnian J. Basic Med. Sci. 18, 8. https:\/\/doi.org\/10.17305\/bjbms.2018.2756 (2018).","journal-title":"Bosnian J. Basic Med. Sci."},{"key":"70871_CR7","doi-asserted-by":"publisher","unstructured":"7Po, A. et al. Noncanonical GLI1 signalling promotes stemness features and in-vivo growth in lung adenocarcinoma Oncogene, https:\/\/doi.org\/10.1038\/onc.2017.91 (2017).","DOI":"10.1038\/onc.2017.91"},{"key":"70871_CR8","doi-asserted-by":"publisher","first-page":"14048","DOI":"10.1074\/jbc.M611089200","volume":"282","author":"Z Ji","year":"2007","unstructured":"Ji, Z., Mei, F. C., Xie, J. & Cheng, X. Oncogenic KRAS activates hedgehog signaling pathway in pancreatic cancer cells. J. Biol. Chem. 282, 14048\u201314055. https:\/\/doi.org\/10.1074\/jbc.M611089200 (2007).","journal-title":"J. Biol. Chem."},{"key":"70871_CR9","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.3390\/ijms19041098","volume":"19","author":"T Usui","year":"2018","unstructured":"Usui, T. et al. Hedgehog signals mediate anti-cancer drug resistance in three-dimensional primary colorectal cancer organoid culture. Int. J. Mol. Sci. 19, 1098. https:\/\/doi.org\/10.3390\/ijms19041098 (2018).","journal-title":"Int. J. Mol. Sci."},{"key":"70871_CR10","doi-asserted-by":"publisher","first-page":"4874","DOI":"10.1038\/onc.2011.195","volume":"30","author":"R Singh","year":"2011","unstructured":"Singh, R. et al. ABCG2 is a direct transcriptional target of hedgehog signaling and involved in stroma-induced drug tolerance in diffuse large B-cell lymphoma. Oncogene 30, 4874\u20134886. https:\/\/doi.org\/10.1038\/onc.2011.195 (2011).","journal-title":"Oncogene"},{"key":"70871_CR11","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1002\/mc.22015","volume":"53","author":"Y Chen","year":"2014","unstructured":"Chen, Y., Bieber, M. & Teng, N. Hedgehog signaling regulates drug sensitivity by targeting ABC transporters ABCB1 and ABCG2 in epithelial ovarian cancer. Mol. Carcinog. 53, 625\u2013634. https:\/\/doi.org\/10.1002\/mc.22015 (2014).","journal-title":"Mol. Carcinog."},{"key":"70871_CR12","doi-asserted-by":"publisher","unstructured":"12Brenner, H., Kloor, M. & Pox, C. P. Colorectal cancer. Lancet 383, https:\/\/doi.org\/10.1016\/S0140-6736(13)61649-9 (2014).","DOI":"10.1016\/S0140-6736(13)61649-9"},{"key":"70871_CR13","doi-asserted-by":"publisher","first-page":"4492","DOI":"10.18632\/oncotarget.2046","volume":"5","author":"A Agyeman","year":"2014","unstructured":"Agyeman, A., Jha, B., Mazumdar, T. & Houghton, J. Mode and specificity of binding of the small molecule GANT61 to GLI determines inhibition of GLI-DNA binding. Oncotarget 5, 4492. https:\/\/doi.org\/10.18632\/oncotarget.2046 (2014).","journal-title":"Oncotarget"},{"key":"70871_CR14","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1038\/cdd.2015.56","volume":"22","author":"S Pandolfi","year":"2015","unstructured":"Pandolfi, S., Montagnani, V., Lapucci, A. & Stecca, B. HEDGEHOG\/GLI-E2F1 axis modulates iASPP expression and function and regulates melanoma cell growth. Cell Death Differ. 22, 2006\u20132019. https:\/\/doi.org\/10.1038\/cdd.2015.56 (2015).","journal-title":"Cell Death Differ."},{"key":"70871_CR15","doi-asserted-by":"publisher","first-page":"4147","DOI":"10.1158\/1078-0432.CCR-06-0038","volume":"12","author":"AD Yang","year":"2006","unstructured":"Yang, A. D. et al. Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines. Clin. Cancer Res. 12, 4147\u20134153. https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-0038 (2006).","journal-title":"Clin. Cancer Res."},{"key":"70871_CR16","unstructured":"16R2. R2: Genomics Analysis and Visualization Platform, https:\/\/r2.amc.nl."},{"key":"70871_CR17","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-0753","author":"T Oka","year":"2007","unstructured":"Oka, T., Sasaki, S., Ajioka, Y., Muto, T. & Nagawa, H. Gene expression signature and the prediction of ulcerative colitis^ associated colorectal cancer by DNA microarray. Clin. Cancer Res. https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-0753 (2007).","journal-title":"Clin. Cancer Res."},{"key":"70871_CR18","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/sj.bjc.6605515","volume":"102","author":"O Galamb","year":"2010","unstructured":"Galamb, O. et al. Reversal of gene expression changes in the colorectal normal-adenoma pathway by NS398 selective COX2 inhibitor. Br. J. Cancer 102, 765\u2013773. https:\/\/doi.org\/10.1038\/sj.bjc.6605515 (2010).","journal-title":"Br. J. Cancer"},{"key":"70871_CR19","doi-asserted-by":"publisher","unstructured":"19Celia Chao, M., Carmical, J. R. & BA, T. G. W. The CD133-positive colon cancer cell phenotype is more interactive with the tumor microenvironment compared to CD133-negative cell. Lab. Invest. 92, 420\u2013436, https:\/\/doi.org\/10.1038\/labinvest.2011.185 (2012).","DOI":"10.1038\/labinvest.2011.185"},{"key":"70871_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.coph.2017.04.006","volume":"35","author":"ME Fiori","year":"2017","unstructured":"Fiori, M. E., Villanova, L. & De Maria, R. Cancer stem cells: At the forefront of personalized medicine and immunotherapy. Curr. Opin. Pharmacol. 35, 1\u201311. https:\/\/doi.org\/10.1016\/j.coph.2017.04.006 (2017).","journal-title":"Curr. Opin. Pharmacol."},{"key":"70871_CR21","doi-asserted-by":"publisher","first-page":"6876","DOI":"10.3748\/wjg.v22.i30.6876","volume":"22","author":"T Hu","year":"2016","unstructured":"Hu, T., Li, Z., Gao, C.-Y. & Cho, C. H. Mechanisms of drug resistance in colon cancer and its therapeutic strategies. World J. Gastroenterol. 22, 6876. https:\/\/doi.org\/10.3748\/wjg.v22.i30.6876 (2016).","journal-title":"World J. Gastroenterol."},{"key":"70871_CR22","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1111\/cas.13097","volume":"107","author":"M Kobayashi","year":"2016","unstructured":"Kobayashi, M., Funayama, R., Ohnuma, S., Unno, M. & Nakayama, K. Wnt-\u03b2-catenin signaling regulates ABCC 3 (MRP 3) transporter expression in colorectal cancer. Cancer Sci. 107, 1776\u20131784. https:\/\/doi.org\/10.1111\/cas.13097 (2016).","journal-title":"Cancer Sci."},{"key":"70871_CR23","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.cellsig.2019.01.013","volume":"57","author":"D Tang","year":"2019","unstructured":"Tang, D. et al. Inhibition of MALAT1 reduces tumor growth and metastasis and promotes drug sensitivity in colorectal cancer. Cell. Signal. 57, 21\u201328. https:\/\/doi.org\/10.1016\/j.cellsig.2019.01.013 (2019).","journal-title":"Cell. Signal."},{"key":"70871_CR24","doi-asserted-by":"publisher","first-page":"5458","DOI":"10.1002\/jcp.26406","volume":"233","author":"HH Hsu","year":"2018","unstructured":"Hsu, H. H. et al. Oxaliplatin resistance in colorectal cancer cells is mediated via activation of ABCG2 to alleviate ER stress induced apoptosis. J. Cell. Physiol. 233, 5458\u20135467. https:\/\/doi.org\/10.1002\/jcp.26406 (2018).","journal-title":"J. Cell. Physiol."},{"key":"70871_CR25","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.3109\/00365521.2015.1056224","volume":"50","author":"TI Kopp","year":"2015","unstructured":"Kopp, T. I., Andersen, V., Tjonneland, A. & Vogel, U. Polymorphisms in ATP-binding cassette transporter genes and interaction with diet and life style factors in relation to colorectal cancer in a Danish prospective case-cohort study. Scand. J. Gastroenterol. 50, 1469\u20131481. https:\/\/doi.org\/10.3109\/00365521.2015.1056224 (2015).","journal-title":"Scand. J. Gastroenterol."},{"key":"70871_CR26","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1097\/FPC.0000000000000168","volume":"25","author":"S Chen","year":"2015","unstructured":"Chen, S. et al. ABCC5 and ABCG1 polymorphisms predict irinotecan-induced severe toxicity in metastatic colorectal cancer patients. Pharmacogenet. Genomics 25, 573\u2013583. https:\/\/doi.org\/10.1097\/FPC.0000000000000168 (2015).","journal-title":"Pharmacogenet. Genomics"},{"key":"70871_CR27","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.phrs.2018.08.026","volume":"136","author":"S Salvador-Mart\u00edn","year":"2018","unstructured":"Salvador-Mart\u00edn, S. et al. Clinical utility of ABCB1 genotyping for preventing toxicity in treatment with irinotecan. Pharmacol. Res. 136, 133\u2013139. https:\/\/doi.org\/10.1016\/j.phrs.2018.08.026 (2018).","journal-title":"Pharmacol. Res."},{"key":"70871_CR28","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13578-017-0145-7","volume":"7","author":"L Zhang","year":"2017","unstructured":"Zhang, L. et al. The role of GLI1 for 5-Fu resistance in colorectal cancer. Cell Biosci. 7, 17. https:\/\/doi.org\/10.1186\/s13578-017-0145-7 (2017).","journal-title":"Cell Biosci."},{"key":"70871_CR29","doi-asserted-by":"publisher","first-page":"19719","DOI":"10.1073\/pnas.1113021108","volume":"108","author":"EJ Tarling","year":"2011","unstructured":"Tarling, E. J. & Edwards, P. A. ATP binding cassette transporter G1 (ABCG1) is an intracellular sterol transporter. Proc. Natl. Acad. Sci. 108, 19719\u201319724. https:\/\/doi.org\/10.1073\/pnas.1113021108 (2011).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"70871_CR30","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.canlet.2019.03.011","volume":"453","author":"EA Roundhill","year":"2019","unstructured":"Roundhill, E. A., Jabri, S. & Burchill, S. A. ABCG1 and Pgp identify drug resistant, self-renewing osteosarcoma cells. Cancer Lett. 453, 142\u2013157. https:\/\/doi.org\/10.1016\/j.canlet.2019.03.011 (2019).","journal-title":"Cancer Lett."},{"key":"70871_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-019-6480-9","volume":"20","author":"X Liao","year":"2020","unstructured":"Liao, X. et al. Oxaliplatin resistance is enhanced by saracatinib via upregulation Wnt-ABCG1 signaling in hepatocellular carcinoma. BMC Cancer 20, 1\u201312. https:\/\/doi.org\/10.1186\/s12885-019-6480-9 (2020).","journal-title":"BMC Cancer"},{"key":"70871_CR32","doi-asserted-by":"publisher","first-page":"2592","DOI":"10.1002\/ijc.29991","volume":"138","author":"Y Wang","year":"2016","unstructured":"Wang, Y. et al. Genetic variants in ABCG 1 are associated with survival of nonsmall-cell lung cancer patients. Int. J. Cancer 138, 2592\u20132601. https:\/\/doi.org\/10.1002\/ijc.29991 (2016).","journal-title":"Int. J. Cancer"},{"key":"70871_CR33","doi-asserted-by":"publisher","unstructured":"33Moon, S.-H. et al. p53 represses the mevalonate pathway to mediate tumor suppression. Cell 176, 564\u2013580. e519, https:\/\/doi.org\/10.1016\/j.cell.2018.11.011 (2019).","DOI":"10.1016\/j.cell.2018.11.011"},{"key":"70871_CR34","doi-asserted-by":"publisher","unstructured":"34Stecca, B. & Ruiz i Altaba, A. A GLI1-p53 inhibitory loop controls neural stem cell and tumour cell numbers. EMBO J 28, 663\u2013676, https:\/\/doi.org\/10.1038\/emboj.2009.16 (2009).","DOI":"10.1038\/emboj.2009.16"},{"key":"70871_CR35","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1002\/humu.22556","volume":"35","author":"B Leroy","year":"2014","unstructured":"Leroy, B. et al. Analysis of TP 53 mutation status in human cancer cell lines: A reassessment. Hum. Mutat. 35, 756\u2013765. https:\/\/doi.org\/10.1002\/humu.22556 (2014).","journal-title":"Hum. Mutat."},{"key":"70871_CR36","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1038\/nm.3389","volume":"19","author":"D Amakye","year":"2013","unstructured":"Amakye, D., Jagani, Z. & Dorsch, M. Unraveling the therapeutic potential of the Hedgehog pathway in cancer. Nat. Med. 19, 1410\u20131422. https:\/\/doi.org\/10.1038\/nm.3389 (2013).","journal-title":"Nat. Med."},{"key":"70871_CR37","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1158\/1078-0432.CCR-12-1800","volume":"19","author":"J Berlin","year":"2013","unstructured":"Berlin, J. et al. A randomized phase II trial of vismodegib versus placebo with FOLFOX or FOLFIRI and bevacizumab in patients with previously untreated metastatic colorectal cancer. Clin. Cancer Res. 19, 258\u2013267. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-1800 (2013).","journal-title":"Clin. Cancer Res."},{"key":"70871_CR38","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1002\/ijc.28719","volume":"135","author":"K Kerl","year":"2014","unstructured":"Kerl, K. et al. Arsenic trioxide inhibits tumor cell growth in malignant rhabdoid tumors in vitro and in vivo by targeting overexpressed Gli1. Int. J. Cancer 135, 989\u2013995. https:\/\/doi.org\/10.1002\/ijc.28719 (2014).","journal-title":"Int. J. Cancer"},{"key":"70871_CR39","doi-asserted-by":"publisher","first-page":"3019","DOI":"10.1158\/1078-0432.CCR-09-2590","volume":"16","author":"B Ardalan","year":"2010","unstructured":"Ardalan, B. et al. A phase I study of 5-fluorouracil\/leucovorin and arsenic trioxide for patients with refractory\/relapsed colorectal carcinoma. Clin. Cancer Res. 16, 3019\u20133027. https:\/\/doi.org\/10.1158\/1078-0432.CCR-09-2590 (2010).","journal-title":"Clin. Cancer Res."},{"key":"70871_CR40","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1124\/mol.115.100867","volume":"89","author":"B Li","year":"2016","unstructured":"Li, B. et al. Arsenic attenuates GLI signaling, increasing or decreasing its transcriptional program in a context-dependent manner. Mol. Pharmacol. 89, 226\u2013232. https:\/\/doi.org\/10.1124\/mol.115.100867 (2016).","journal-title":"Mol. Pharmacol."},{"key":"70871_CR41","doi-asserted-by":"publisher","unstructured":"41Veschi, V. et al. Targeting chemoresistant colorectal cancer via systemic administration of a BMP7 variant. Oncogene, 1\u201317, https:\/\/doi.org\/10.1038\/s41388-019-1047-4.","DOI":"10.1038\/s41388-019-1047-4"},{"key":"70871_CR42","doi-asserted-by":"publisher","unstructured":"42Miele, E. et al. The histone methyltransferase EZH2 as a druggable target in SHH medulloblastoma cancer stem cells. Oncotarget 8, 68557, https:\/\/doi.org\/10.18632\/oncotarget.19782 (2017).","DOI":"10.18632\/oncotarget.19782"},{"issue":"1603\u20131611","key":"70871_CR43","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1039\/c5mb00034c","volume":"11","author":"M Ronci","year":"2015","unstructured":"Ronci, M. et al. Proteomic analysis of human sonic hedgehog (SHH) medulloblastoma stem-like cells. Mol. Biosyst. 11(1603\u20131611), 19. https:\/\/doi.org\/10.1039\/c5mb00034c (2015).","journal-title":"Mol. Biosyst."},{"key":"70871_CR44","doi-asserted-by":"publisher","first-page":"3523","DOI":"10.1038\/s41598-018-21876-y","volume":"8","author":"ZM Besharat","year":"2018","unstructured":"Besharat, Z. M. et al. Foxm1 controls a pro-stemness microRNA network in neural stem cells. Sci. Rep. 8, 3523. https:\/\/doi.org\/10.1038\/s41598-018-21876-y (2018).","journal-title":"Sci. Rep."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-70871-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-70871-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-70871-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T18:21:20Z","timestamp":1670350880000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-70871-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,19]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["70871"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-70871-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,19]]},"assertion":[{"value":"17 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13988"}}